Daratumumab plus bortezomib-melphalan-prednisone (VMP) in elderly (≥75 y) patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE).

8031Background: Daratumumab (D) plus VMP (D-VMP) prolonged progression-free survival (PFS) compared with VMP and was well-tolerated in the phase 3 ALCYONE study (NCT02195479). We examined the effic...